Chemotherapy

Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting

Retrieved on:

Thursday, May 20, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medical specialties, Medicine, Cancer treatments, Immunology, Interleukins, Cancer immunotherapy, Chemotherapy, Interleukin 2, Cancer

b'Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced today the presentation of data from preclinical studies of XTX202, its tumor-selective interleukin-2 (IL-2) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with no systemic toxicity observed.

Key Points:

b'Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced today the presentation of data from preclinical studies of XTX202, its tumor-selective interleukin-2 (IL-2) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with no systemic toxicity observed.
The data will be reported in a poster entitled \xe2\x80\x9cXTX202, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates\xe2\x80\x9d at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
We are excited to present these data which, for the first time, demonstrate selective tumor-inhibition and favorable tolerability of XTX202 in preclinical models.
For more information, please visit www.xiliotx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210520005158/en/\n'

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Retrieved on:

Wednesday, May 19, 2021

Biotechnology, Pharmaceutical, Health, Oncology, Clinical medicine, Medicine, Clovis Oncology, Cancer treatments, Clovis, Chemotherapy, Oncology, Health, Rubraca (rucaparib), Lucitanib, Clovis Oncology, RUBRACA (RUCAPARIB), LUCITANIB, CLOVIS ONCOLOGY

Safety profiles for Rubraca and chemotherapy across the subgroups were consistent with known safety profiles of these agents.

Key Points:

Safety profiles for Rubraca and chemotherapy across the subgroups were consistent with known safety profiles of these agents.
While evidence of clinical activity has been observed, Clovis does not believe that the interim efficacy data support further development in non-clear cell OC.
Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.
Clovis Oncology does not undertake to update or revise any forward-looking statements.

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

Retrieved on:

Wednesday, May 19, 2021

Clinical medicine, Medicine, Cancer, Antineoplastic drugs, Cancer treatments, Oncology, Chemotherapy, Occupational safety and health, Stapled peptide

and Lodovico Balducci, M.D., discussing the unmet need in addressing chemotherapy-induced toxicities, the resulting medical impact and quality-of-life burden on cancer patients, as well as the opportunity for a new paradigm known as chemoprotection that focuses on proactive prevention.\nDr.

Key Points:

and Lodovico Balducci, M.D., discussing the unmet need in addressing chemotherapy-induced toxicities, the resulting medical impact and quality-of-life burden on cancer patients, as well as the opportunity for a new paradigm known as chemoprotection that focuses on proactive prevention.\nDr.
Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy while ensuring we do not protect cancer cells.
As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells.
By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients\xe2\x80\x99 quality of life and help them better tolerate chemotherapy.

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Retrieved on:

Friday, May 21, 2021

While concurrent chemoradiation is the non-surgical standard of care, not all patients can tolerate platinum-based chemotherapy (e.g., cisplatin).

Key Points:

While concurrent chemoradiation is the non-surgical standard of care, not all patients can tolerate platinum-based chemotherapy (e.g., cisplatin).
Primary endpoints of the study are objective response rate (ORR) and complete response rate (CRR) of the primary tumor.
Six (6) serious adverse events (SAEs) related to NBTXR3 were observed across five (5) patients.
The long-term safety profile of NBTXR3, together with its efficacy data, further supported a favorable benefit-risk ratio for patients with STS.

Pivotal Phase III Data at ASCO Show Genentech’s Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning

Retrieved on:

Wednesday, May 19, 2021

In this population, Tecentriq increased DFS by a median of seven months (42.3 months vs. 35.3 months with BSC).

Key Points:

In this population, Tecentriq increased DFS by a median of seven months (42.3 months vs. 35.3 months with BSC).
Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.
It was the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer in combination with carboplatin and etoposide (chemotherapy).
Tecentriq also has four approved indications in NSCLC as either a single agent or in combination with targeted therapies and/or chemotherapies.

Breast Cancer Treatments Do Not Increase Risk of Covid-19 Infection or Death

Retrieved on:

Wednesday, May 19, 2021

Medicine, Clinical medicine, Cancer, Cancer treatments, Antineoplastic drugs, Breast cancer, Chemotherapy, Metastatic breast cancer, Alternative cancer treatments

b'NEW YORK, May 19, 2021 /PRNewswire/ --Cancer drugs capable of weakening the body\'s immune defenses are no more likely to increase the risk of Covid-19 infection or death than breast cancer therapies that do not undermine the immune system, a new study shows.

Key Points:

b'NEW YORK, May 19, 2021 /PRNewswire/ --Cancer drugs capable of weakening the body\'s immune defenses are no more likely to increase the risk of Covid-19 infection or death than breast cancer therapies that do not undermine the immune system, a new study shows.
Researchers say the results challenge initial concerns that such treatments, which poison cancer cells, were too dangerous to continue during the pandemic.\nLed by researchers at NYU Langone Health and its Perlmutter Cancer Center, the new investigation involving over 3,000 women treated for breast cancer at the height of the pandemic in New York City showed that only 64, or 2 percent, contracted the virus.
Many physicians, the study authors say, were particularly concerned about giving standard chemotherapy regimens, potentially making patients more vulnerable to the virus.
The investigators then analyzed information including COVID-19 testing results, the extent of cancer, the presence of other illnesses, and survival.\nAmong the study results, the risk of coronavirus infection among breast cancer patients who received chemotherapy was not greater than the risk for those who received treatments that were not expected to hinder their immune systems.

Boundless Bio Announces Educational Session on Extrachromosomal DNA (ecDNA) at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on:

Monday, May 17, 2021

General Health, Health, Science, Research, Oncology, Cancer, Clinical medicine, Medicine, Oncology, Carcinogenesis, DNA, Chromosomes, Cancer treatments, Extrachromosomal DNA, Oncogene, Centromere, Chemotherapy

b'Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA lacking centromeres but containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Key Points:

b'Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA lacking centromeres but containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.
ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
By leveraging the plasticity afforded by ecDNA, cancer has the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells\xe2\x80\x99 primary mechanisms of recurrence and treatment resistance.
ecDNA are not found in healthy cells but are present in many solid tumor cancers.

G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer

Retrieved on:

Monday, May 17, 2021

Clinical medicine, Cancer, Medicine, Lung cancer, Oncology, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Trilaciclib, Bone marrow suppression, Chemotherapy

( poster )\nThe first poster details a cost-benefit model estimating the economic value from a U.S. commercial payer perspective of using COSELA\xe2\x84\xa2 (trilaciclib) prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Key Points:

( poster )\nThe first poster details a cost-benefit model estimating the economic value from a U.S. commercial payer perspective of using COSELA\xe2\x84\xa2 (trilaciclib) prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
( poster )\nThe second poster quantifies the impact of treatment-induced myelosuppression among Medicare patients diagnosed with SCLC, thereby contributing to the growing body of scientific evidence demonstrating the significant health burden, economic toll, and health-related quality-of-life effects of chemotherapy-induced myelosuppression.
\xe2\x80\x9cThese analyses add to the data that help clarify the potential positive financial impact of COSELA usage and the projected real-world economic value of COSELA.
SCLC, one of the two main types of lung cancer, accounts for about 10% to 15% of all lung cancers.

Global Silver (Demand, Supply & Production) Market Insights & Forecast 2021-2025 - ResearchAndMarkets.com

Retrieved on:

Friday, May 14, 2021

Retail, Other Retail, Chemical elements, Chemistry, Physical sciences, Silver, Precious metals, Bullion coins, Chemotherapy, Silver nanoparticle

b'The "Global Silver Market (Demand, Supply & Production): Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com\'s offering.\nThe global silver demand is expected to reach 1,155 million ounces in 2025, growing at a CAGR of 2.98%, for the time period of 2021-2025.

Key Points:

b'The "Global Silver Market (Demand, Supply & Production): Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com\'s offering.\nThe global silver demand is expected to reach 1,155 million ounces in 2025, growing at a CAGR of 2.98%, for the time period of 2021-2025.
However, the market growth would be challenged by volatile prices of silver and environmental impact of silver nanoparticles.\nA few notable trends may include rising use of silver in auto industry, growing consumption of silver nanoparticles and upsurge in the silver consumption in the U.S.\nThe silver market is emerging gradually over years and securing its position in financial markets in the modern economy.
Given its size and liquidity, silver is clearly becoming a monetary asset for investors.\nFurther, the expanding range of application is making silver highly demanded across various end industries.
It was followed by Central & South America as of the emerging regions in the silver market due to the increase in exploration activities for the silver production.

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Retrieved on:

Thursday, May 13, 2021

Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer, Chemotherapy, Oncology, Chemotherapy-induced peripheral neuropathy, Taxane, Breast cancer, Causes of cancer pain, OSM-0205 and CIPN, Osmol Therapeutics, OSM-0205 AND CIPN, OSMOL THERAPEUTICS

b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Key Points:

b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).
OSM-0205\xe2\x80\x99s mechanism addresses the off-target toxicity of microtubule-based chemotherapy agents that results in a calcium surge leading to CIPN.
Taxanes are the most widely used chemotherapy treatment for breast cancer and can lead to CIPN in up to 80% of patients.
The company\xe2\x80\x99s lead indication will be for the prevention of CIPN in breast cancer patients treated with taxane-based therapy, a treatment regimen in which up to 80% of patients experience CIPN.